SlideShare a Scribd company logo
Plague
CDC, AFIP
Diseases of Bioterrorist Potential
Learning Objectives
 Describe the epidemiology, mode of transmission, and
presenting symptoms of disease caused by the CDC-
defined Category A agents
 Identify the infection control and prophylactic measures
to implement in the event of a suspected or confirmed
Category A case or outbreak
Plague
History & Significance
14th Century: “Black Death” responsible for >20
million deaths in Europe
Used as a BW agent by Japan in WW II
Studied by Soviet and, to a smaller extent, U.S.
BW programs
1995: Larry Wayne Harris arrested for illicit
procurement of culture via mail
Plague
Epidemiology
Caused by Yersinia pestis
About 10-15 cases/year U.S.
 Mainly SW states
Human plague occurs from bite of an infected flea
(bubonic)
Only pneumonic form of plague is spread person-to-
person
 Last case of person-to-person transmission in U.S. occurred in 1924
Yersinia Pestis
 Gram negative, non-
motile, non-spore-
forming bacillus
 Resistant to freezing
temperature and
drying, killed by heat
and sunlight Source: Centers for Disease Control and
Prevention, Division of Vector-Borne
Infectious Diseases, Fort Collins, CO
Plague
Case Definition
• Characterized by fever, chills, headache, malaise,
prostration, & leukocytosis that manifests in one
or more of the following clinical forms:
– Regional lymphadenitis (bubonic)
– Septicemia w/o evident bubo (septicemic)
– Plague pneumonia
– Pharyngitis & cervical lymphadenitis (pharyngeal)
MMWR 1997;46(RR-10)
Plague
Case Definition, cont.
Laboratory criteria for diagnosis:
Presumptive
Elevated serum antibody titers to Y. pestis F1 antigen (w/o
documented 4-fold change) in a patient with no history of plague
vaccination OR
Detection of F1 antigen in a clinical specimen by fluorescent assay
Confirmatory
Isolation of Y. pestis from a clinical specimen OR
4-fold or greater change in serum antibody titer to Y. pestis F1 antigen
MMWR 1997;46(RR-10)
Plague: Case Classification
Suspected: Clinically compatible case w/o
presumptive or confirmatory lab results
Probable: Clinically compatible case with
presumptive lab results
Confirmed: Clinically compatible case with
confirmatory lab results
MMWR 1997;46(RR-10)
Plague
Clinical Forms
 Bubonic plague
Most common naturally-occurring form
Mortality 60% untreated, <5% treated
 Primary or secondary septicemic plague
 Pneumonic plague
Most likely BT presentation
From aerosol or septicemic spread to lungs
Survival unlikely if treatment not initiated w/in
24 hours of the onset of symptoms
Pneumonic Plague
Clinical Presentation
Incubation: 1-6 days (usually 2-4 days)
Acute onset of fever with cough, dyspnea, and chest pain
Hemoptysis characteristic; watery or purulent sputum
also possible
Prominent GI symptoms may be present, including
nausea, vomiting, diarrhea, and abdominal pain
Pneumonic Plague
Clinical Presentation
Other symptoms include headache, chills,
malaise, myalgias
Rarely, cervical bubo present
Rapid progression to respiratory failure & shock
Bubonic Plague
 Incubation: 2-8 days
 Sudden onset nonspecific symptoms: fever, chills,
malaise, muscle aches, headache
 Regional lymphadenitis (buboes)
Swollen, very painful lymph nodes
Typically inguinal, femoral, axillary, or cervical
Erythema overlying skin
May have surrounding edema
Concurrent with or shortly after onset of other symptoms
Septicemic & Bubonic Plague
Source: CDC NVBID
Plague
Infection Control
Person-to-person transmission via respiratory
droplets
Standard respiratory droplet precautions
Treatment = 10 days antibiotics
 Case isolation for at least the first 48 hrs of antibiotic
treatment
Bubonic plague - standard precautions
Plague
Infection Control
Antibiotic prophylaxis for close contacts
Duration: 7 days or duration of risk of exposure +
7 days
Close contacts refusing prophylaxis:
Observe 7 days after last exposure and treat if
fever or cough develop
Bubonic contacts:
Observe 7d and treat if symptoms develop
Plague
Summary of Key Points
The most likely presentation in a BT attack is
pneumonic plague.
Unlike other forms of plague, pneumonic plague
is transmitted person to person, and thus
respiratory droplet precautions are indicated in
suspected cases until 48 hours after the initiation
of antibiotic therapy.
Case Reports
 Plague
Plague Pneumonia - CA. MMWR 1984;33(34)
Pneumonic Plague -- Arizona, 1992. MMWR 41(40)
Resources
 Centers for Disease Control & Prevention
 Bioterrorism Web page:
 CDC Office of Health and Safety Information System
(personal protective equipment)
 USAMRIID -- includes link to on-line version
of Medical Management of Biological Casualties
Handbook http://www.usamriid.army.mil/
http://www.bt.cdc.gov/
http://www.cdc.gov/od/ohs/
Resources
 Office of the Surgeon General: Medical
Nuclear, Biological and Chemical Information
 St. Louis University Center for the Study of
Bioterrorism and Emerging Infections
http://www.nbc-med.org
http://bioterrorism.slu.edu

More Related Content

Similar to plague(1).ppt

Coronavirus (COVID-19)
Coronavirus (COVID-19) Coronavirus (COVID-19)
Coronavirus (COVID-19)
Belachew Weldegebriel
 
Bioterrorism
BioterrorismBioterrorism
Bioterrorism
drguru007
 
Swine flu in pregnancy
Swine flu in pregnancySwine flu in pregnancy
Swine flu in pregnancy
dr.hafsa asim
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)
D.A.B.M
 
viralpneumonia influenza.pptx
viralpneumonia influenza.pptxviralpneumonia influenza.pptx
viralpneumonia influenza.pptx
Ashraf Shaik
 
H1 n1 swine flu
H1 n1 swine fluH1 n1 swine flu
H1 n1 swine flu
Dr. Ashish kumar
 
Pneumonia Pediatric
Pneumonia PediatricPneumonia Pediatric
Pneumonia Pediatric
Dr V K Pandey
 
Epidemiology H1N1 Influenza (Swine Flu)
Epidemiology  H1N1  Influenza (Swine Flu)Epidemiology  H1N1  Influenza (Swine Flu)
Epidemiology H1N1 Influenza (Swine Flu)
Prabesh Ghimire
 
Swine Flu Update Dec'09
Swine Flu Update Dec'09Swine Flu Update Dec'09
Swine Flu Update Dec'09
Prasad Waingankar
 
Bioterrorism
BioterrorismBioterrorism
Bioterrorism
Rikin Hasnani
 
bioterrorism-170215073558.pdf
bioterrorism-170215073558.pdfbioterrorism-170215073558.pdf
bioterrorism-170215073558.pdf
NamanMishra87
 
Introspecting into Swine flu: Current updates
Introspecting into Swine flu: Current updatesIntrospecting into Swine flu: Current updates
Introspecting into Swine flu: Current updates
Arnab Nandy
 
Vaccine3 polio
Vaccine3 polioVaccine3 polio
Vaccine3 polio
Jasmine John
 
Swine Flu
Swine FluSwine Flu
Swine Flu
ohogi
 
Childhood Pneumonia 2017, BSMMU, Bangladesh.
Childhood Pneumonia 2017, BSMMU, Bangladesh.Childhood Pneumonia 2017, BSMMU, Bangladesh.
Childhood Pneumonia 2017, BSMMU, Bangladesh.
abdullahel amaan
 
Corona virus
Corona virus Corona virus
Corona virus
shashi gupta
 
investigation of an epidemic
investigation of an epidemicinvestigation of an epidemic
investigation of an epidemic
Bala Vidyadhar
 
H1 N1
H1 N1H1 N1
Pharmacotherapy of Tuberculosis
Pharmacotherapy of TuberculosisPharmacotherapy of Tuberculosis
Pharmacotherapy of Tuberculosis
Koppala RVS Chaitanya
 
PNEUMONIA.pptx
PNEUMONIA.pptxPNEUMONIA.pptx
PNEUMONIA.pptx
SaadMohdBello
 

Similar to plague(1).ppt (20)

Coronavirus (COVID-19)
Coronavirus (COVID-19) Coronavirus (COVID-19)
Coronavirus (COVID-19)
 
Bioterrorism
BioterrorismBioterrorism
Bioterrorism
 
Swine flu in pregnancy
Swine flu in pregnancySwine flu in pregnancy
Swine flu in pregnancy
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)
 
viralpneumonia influenza.pptx
viralpneumonia influenza.pptxviralpneumonia influenza.pptx
viralpneumonia influenza.pptx
 
H1 n1 swine flu
H1 n1 swine fluH1 n1 swine flu
H1 n1 swine flu
 
Pneumonia Pediatric
Pneumonia PediatricPneumonia Pediatric
Pneumonia Pediatric
 
Epidemiology H1N1 Influenza (Swine Flu)
Epidemiology  H1N1  Influenza (Swine Flu)Epidemiology  H1N1  Influenza (Swine Flu)
Epidemiology H1N1 Influenza (Swine Flu)
 
Swine Flu Update Dec'09
Swine Flu Update Dec'09Swine Flu Update Dec'09
Swine Flu Update Dec'09
 
Bioterrorism
BioterrorismBioterrorism
Bioterrorism
 
bioterrorism-170215073558.pdf
bioterrorism-170215073558.pdfbioterrorism-170215073558.pdf
bioterrorism-170215073558.pdf
 
Introspecting into Swine flu: Current updates
Introspecting into Swine flu: Current updatesIntrospecting into Swine flu: Current updates
Introspecting into Swine flu: Current updates
 
Vaccine3 polio
Vaccine3 polioVaccine3 polio
Vaccine3 polio
 
Swine Flu
Swine FluSwine Flu
Swine Flu
 
Childhood Pneumonia 2017, BSMMU, Bangladesh.
Childhood Pneumonia 2017, BSMMU, Bangladesh.Childhood Pneumonia 2017, BSMMU, Bangladesh.
Childhood Pneumonia 2017, BSMMU, Bangladesh.
 
Corona virus
Corona virus Corona virus
Corona virus
 
investigation of an epidemic
investigation of an epidemicinvestigation of an epidemic
investigation of an epidemic
 
H1 N1
H1 N1H1 N1
H1 N1
 
Pharmacotherapy of Tuberculosis
Pharmacotherapy of TuberculosisPharmacotherapy of Tuberculosis
Pharmacotherapy of Tuberculosis
 
PNEUMONIA.pptx
PNEUMONIA.pptxPNEUMONIA.pptx
PNEUMONIA.pptx
 

Recently uploaded

Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 

Recently uploaded (20)

Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 

plague(1).ppt

  • 2. Diseases of Bioterrorist Potential Learning Objectives  Describe the epidemiology, mode of transmission, and presenting symptoms of disease caused by the CDC- defined Category A agents  Identify the infection control and prophylactic measures to implement in the event of a suspected or confirmed Category A case or outbreak
  • 3. Plague History & Significance 14th Century: “Black Death” responsible for >20 million deaths in Europe Used as a BW agent by Japan in WW II Studied by Soviet and, to a smaller extent, U.S. BW programs 1995: Larry Wayne Harris arrested for illicit procurement of culture via mail
  • 4. Plague Epidemiology Caused by Yersinia pestis About 10-15 cases/year U.S.  Mainly SW states Human plague occurs from bite of an infected flea (bubonic) Only pneumonic form of plague is spread person-to- person  Last case of person-to-person transmission in U.S. occurred in 1924
  • 5. Yersinia Pestis  Gram negative, non- motile, non-spore- forming bacillus  Resistant to freezing temperature and drying, killed by heat and sunlight Source: Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, CO
  • 6. Plague Case Definition • Characterized by fever, chills, headache, malaise, prostration, & leukocytosis that manifests in one or more of the following clinical forms: – Regional lymphadenitis (bubonic) – Septicemia w/o evident bubo (septicemic) – Plague pneumonia – Pharyngitis & cervical lymphadenitis (pharyngeal) MMWR 1997;46(RR-10)
  • 7. Plague Case Definition, cont. Laboratory criteria for diagnosis: Presumptive Elevated serum antibody titers to Y. pestis F1 antigen (w/o documented 4-fold change) in a patient with no history of plague vaccination OR Detection of F1 antigen in a clinical specimen by fluorescent assay Confirmatory Isolation of Y. pestis from a clinical specimen OR 4-fold or greater change in serum antibody titer to Y. pestis F1 antigen MMWR 1997;46(RR-10)
  • 8. Plague: Case Classification Suspected: Clinically compatible case w/o presumptive or confirmatory lab results Probable: Clinically compatible case with presumptive lab results Confirmed: Clinically compatible case with confirmatory lab results MMWR 1997;46(RR-10)
  • 9. Plague Clinical Forms  Bubonic plague Most common naturally-occurring form Mortality 60% untreated, <5% treated  Primary or secondary septicemic plague  Pneumonic plague Most likely BT presentation From aerosol or septicemic spread to lungs Survival unlikely if treatment not initiated w/in 24 hours of the onset of symptoms
  • 10. Pneumonic Plague Clinical Presentation Incubation: 1-6 days (usually 2-4 days) Acute onset of fever with cough, dyspnea, and chest pain Hemoptysis characteristic; watery or purulent sputum also possible Prominent GI symptoms may be present, including nausea, vomiting, diarrhea, and abdominal pain
  • 11. Pneumonic Plague Clinical Presentation Other symptoms include headache, chills, malaise, myalgias Rarely, cervical bubo present Rapid progression to respiratory failure & shock
  • 12. Bubonic Plague  Incubation: 2-8 days  Sudden onset nonspecific symptoms: fever, chills, malaise, muscle aches, headache  Regional lymphadenitis (buboes) Swollen, very painful lymph nodes Typically inguinal, femoral, axillary, or cervical Erythema overlying skin May have surrounding edema Concurrent with or shortly after onset of other symptoms
  • 13. Septicemic & Bubonic Plague Source: CDC NVBID
  • 14. Plague Infection Control Person-to-person transmission via respiratory droplets Standard respiratory droplet precautions Treatment = 10 days antibiotics  Case isolation for at least the first 48 hrs of antibiotic treatment Bubonic plague - standard precautions
  • 15. Plague Infection Control Antibiotic prophylaxis for close contacts Duration: 7 days or duration of risk of exposure + 7 days Close contacts refusing prophylaxis: Observe 7 days after last exposure and treat if fever or cough develop Bubonic contacts: Observe 7d and treat if symptoms develop
  • 16. Plague Summary of Key Points The most likely presentation in a BT attack is pneumonic plague. Unlike other forms of plague, pneumonic plague is transmitted person to person, and thus respiratory droplet precautions are indicated in suspected cases until 48 hours after the initiation of antibiotic therapy.
  • 17. Case Reports  Plague Plague Pneumonia - CA. MMWR 1984;33(34) Pneumonic Plague -- Arizona, 1992. MMWR 41(40)
  • 18. Resources  Centers for Disease Control & Prevention  Bioterrorism Web page:  CDC Office of Health and Safety Information System (personal protective equipment)  USAMRIID -- includes link to on-line version of Medical Management of Biological Casualties Handbook http://www.usamriid.army.mil/ http://www.bt.cdc.gov/ http://www.cdc.gov/od/ohs/
  • 19. Resources  Office of the Surgeon General: Medical Nuclear, Biological and Chemical Information  St. Louis University Center for the Study of Bioterrorism and Emerging Infections http://www.nbc-med.org http://bioterrorism.slu.edu